JP2004531224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004531224A5 JP2004531224A5 JP2002559452A JP2002559452A JP2004531224A5 JP 2004531224 A5 JP2004531224 A5 JP 2004531224A5 JP 2002559452 A JP2002559452 A JP 2002559452A JP 2002559452 A JP2002559452 A JP 2002559452A JP 2004531224 A5 JP2004531224 A5 JP 2004531224A5
- Authority
- JP
- Japan
- Prior art keywords
- adp
- fusion protein
- membrane
- aggregation
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0100119.7A GB0100119D0 (en) | 2001-01-03 | 2001-01-03 | Materials and methods relating to protein aggregation in neurodegenerative disease |
| PCT/GB2002/000005 WO2002059150A2 (en) | 2001-01-03 | 2002-01-02 | Materials and methods relating to protein aggregation in neurodegenerative disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004531224A JP2004531224A (ja) | 2004-10-14 |
| JP2004531224A5 true JP2004531224A5 (https=) | 2005-12-22 |
| JP4580618B2 JP4580618B2 (ja) | 2010-11-17 |
Family
ID=9906201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002559452A Expired - Lifetime JP4580618B2 (ja) | 2001-01-03 | 2002-01-02 | 神経変性疾患におけるタンパク質凝集に関する材料および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7834237B2 (https=) |
| EP (1) | EP1348029B1 (https=) |
| JP (1) | JP4580618B2 (https=) |
| AT (1) | ATE548453T1 (https=) |
| AU (1) | AU2002217310B2 (https=) |
| CA (1) | CA2433535C (https=) |
| DK (1) | DK1348029T3 (https=) |
| ES (1) | ES2382457T3 (https=) |
| GB (1) | GB0100119D0 (https=) |
| PT (1) | PT1348029E (https=) |
| WO (1) | WO2002059150A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0104685D0 (en) * | 2001-02-26 | 2001-04-11 | Leuven K U Res & Dev | Tau-opathy model |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| CN100572392C (zh) * | 2002-07-12 | 2009-12-23 | 阿克松神经科学研究和发展股份有限公司 | 截短tau蛋白 |
| EP1516930A1 (en) * | 2003-09-16 | 2005-03-23 | Georg-August Universität Göttingen | Cellular model of tauopathies for lead identification and drug discovery |
| ATE442588T1 (de) * | 2004-03-31 | 2009-09-15 | Anges Mg Inc | Testverfahren zur identifizierung eines kandidatenarzneistoffs |
| JP4814875B2 (ja) | 2004-05-11 | 2011-11-16 | アキシオジェネシス エージー | ｉｎｖｉｔｒｏ分化細胞に基づく薬物発見のための検定 |
| CN101084204B (zh) | 2004-09-23 | 2012-12-05 | 卫思道制药有限公司 | 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法 |
| US9802992B2 (en) * | 2005-12-06 | 2017-10-31 | Tokyo Metropolitan Institute Of Medical Science | Cell into which protein, which can serve as polymerization nucleus of protein polymer, or polymer thereof is introduced, and method for production of the cell |
| EP2013191B3 (en) | 2006-03-29 | 2019-02-27 | Wista Laboratories Ltd. | 3,7-diamino-10h-phenothiazine salts and their use |
| PL2004155T3 (pl) | 2006-03-29 | 2018-08-31 | Wista Laboratories Ltd. | Inhibitory agregacji białek |
| CA3027974C (en) | 2007-10-03 | 2022-03-15 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
| US8703137B2 (en) | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| EA025033B1 (ru) | 2011-02-11 | 2016-11-30 | Уиста Лэборэтэриз Лтд. | Диаминиевые соли фенотиазина и их применение |
| EP2709728B1 (en) | 2011-05-20 | 2019-01-23 | Oligomerix, Inc. | Tau protease methods of use |
| KR102592614B1 (ko) | 2016-07-25 | 2023-10-24 | 위스타 레보레이토리스 리미티드 | 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage) |
| EP3668891B1 (en) * | 2017-08-16 | 2023-07-26 | Lgv1 S.R.L. | Vtft isoform of a bpifb4 protein for use in neuronal deseases and injuries |
| WO2020201828A1 (en) | 2019-04-05 | 2020-10-08 | Tauc3 Biologics Limited | Anti-tauc3 antibodies and uses thereof |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| CN113943766B (zh) * | 2021-11-26 | 2024-01-26 | 守正创新生物科技(天津)有限公司 | 一种抗糖化寡肽-5（AdP）的制备及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE569430A (https=) * | 1957-07-17 | |||
| GB8724412D0 (en) | 1987-10-19 | 1987-11-25 | Medical Res Council | Protein |
| US5571666A (en) * | 1988-10-28 | 1996-11-05 | Oklahoma Medical Research Foundation | Thiazine dyes used to inactivate HIV in biological fluids |
| JPH0725786A (ja) | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
| US5912410A (en) * | 1990-06-15 | 1999-06-15 | Scios Inc. | Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease |
| JP3210336B2 (ja) | 1991-07-10 | 2001-09-17 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | フルオロケミカル撥水性および撥油性処理組成物 |
| WO1993003369A1 (en) | 1991-08-01 | 1993-02-18 | Voorheis Paul H | Diagnostic method for alzheimer's disease |
| ATE398176T1 (de) | 1991-12-06 | 2008-07-15 | Max Planck Gesellschaft | Phosphorylierungsepitope aus dem tau-protein zur diagnose und behandlung der alzheimer-krankheit |
| GB9316727D0 (en) | 1993-08-12 | 1993-09-29 | Inst Of Psychiatry | Models of alzheimers's disease |
| GB9317193D0 (en) | 1993-08-18 | 1993-10-06 | Zeneca Ltd | Method |
| FR2722695B1 (fr) | 1994-07-22 | 1997-04-25 | Demic Lab Sa | Ustensile de badigeonnage cutane par frottement a usage medical |
| EP0778773A1 (en) | 1994-08-08 | 1997-06-18 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes |
| DE4430091A1 (de) | 1994-08-25 | 1996-02-29 | Bayer Ag | Verwendung von N-substituierten Phenothiazinen |
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US5804601A (en) | 1995-04-10 | 1998-09-08 | Takeda Chemical Industries, Ltd. | Aromatic hydroxamic acid compounds, their production and use |
| US5898094A (en) * | 1996-10-21 | 1999-04-27 | University Of South Florida | Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes |
| WO1999062548A1 (en) * | 1998-06-01 | 1999-12-09 | Advanced Research And Technology Institute | Methods and compositions for diagnosing tauopathies |
| DE19920514A1 (de) * | 1999-05-05 | 2000-11-16 | Boehringer Ingelheim Pharma | Methoden zur Auffindung von Proteasen, die spezifisch membrangebundene Substrate spalten |
| AU2001229619A1 (en) | 2000-01-21 | 2001-07-31 | Pharmacia And Upjohn Company | Transgenic mouse model of human neurodegenerative disease |
| JP2001352860A (ja) | 2000-06-15 | 2001-12-25 | Inst Of Physical & Chemical Res | 老年期痴呆症で生じる神経原線維変化を示すマウス |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| US20030217370A1 (en) * | 2002-05-16 | 2003-11-20 | Giasson Benoit I. | Transgenic animal expressing alpha-synuclein and uses thereof |
| US6953974B2 (en) * | 2003-08-26 | 2005-10-11 | Texas Instruments Incorporated | EEPROM device and method for providing lower programming voltage |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| AU2005286235C1 (en) | 2004-09-23 | 2013-08-22 | TauRx Therapeutics Management Ltd | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including Methylthioninium Chloride (MTC) |
-
2001
- 2001-01-03 GB GBGB0100119.7A patent/GB0100119D0/en not_active Ceased
-
2002
- 2002-01-02 EP EP02734847A patent/EP1348029B1/en not_active Expired - Lifetime
- 2002-01-02 JP JP2002559452A patent/JP4580618B2/ja not_active Expired - Lifetime
- 2002-01-02 AU AU2002217310A patent/AU2002217310B2/en not_active Expired
- 2002-01-02 US US10/451,367 patent/US7834237B2/en not_active Expired - Lifetime
- 2002-01-02 CA CA2433535A patent/CA2433535C/en not_active Expired - Lifetime
- 2002-01-02 ES ES02734847T patent/ES2382457T3/es not_active Expired - Lifetime
- 2002-01-02 WO PCT/GB2002/000005 patent/WO2002059150A2/en not_active Ceased
- 2002-01-02 AT AT02734847T patent/ATE548453T1/de active
- 2002-01-02 PT PT02734847T patent/PT1348029E/pt unknown
- 2002-01-02 DK DK02734847.3T patent/DK1348029T3/da active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004531224A5 (https=) | ||
| Zheng et al. | Rhythmic light flicker rescues hippocampal low gamma and protects ischemic neurons by enhancing presynaptic plasticity | |
| Corsetti et al. | Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse Alzheimer’s disease models | |
| CN1225723A (zh) | 检测针对组织转谷氨酰胺酶(tTG)的抗体的免疫方法,tTG在诊断和治疗控制中的用途,和含tTG的口服药剂 | |
| PT1633189T (pt) | Fragmentos truncados de alfa-sinucleína em doença com corpos de lewy | |
| JP2009544284A5 (https=) | ||
| EA013752B1 (ru) | Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний | |
| Shen et al. | FPS-ZM1 alleviates neuroinflammation in focal cerebral ischemia rats via blocking ligand/RAGE/DIAPH1 pathway | |
| Faustini et al. | Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate | |
| CA2433535A1 (en) | Materials and methods relating to protein aggregation in neurodegenerative disease | |
| Viola et al. | The therapeutic and diagnostic potential of amyloid β oligomers selective antibodies to treat Alzheimer’s disease | |
| Harris et al. | Alzheimer’s disease patient-derived high-molecular-weight tau impairs bursting in hippocampal neurons | |
| Toma et al. | Perivascular neurons instruct 3D vascular lattice formation via neurovascular contact | |
| Iwaide et al. | Classification of amyloidosis and protein misfolding disorders in animals 2024: A review on pathology and diagnosis | |
| Wintgens et al. | Plasma myostatin measured by a competitive ELISA using a highly specific antiserum | |
| CA3138808A1 (en) | Detection of biomarkers associated with brugada syndrome | |
| TW562926B (en) | Method for testing renal diseases | |
| Hawkes et al. | Immunotherapy as treatment for Alzheimer’s disease | |
| Xie et al. | Raptin, a sleep-induced hypothalamic hormone, suppresses appetite and obesity | |
| Martinez-Rivas et al. | A mouse model of cardiac immunoglobulin light chain amyloidosis reveals insights into tissue accumulation and toxicity of amyloid fibrils | |
| CN120721981B (zh) | scEMC10在治疗和诊断脑血管内皮细胞衰老中的应用 | |
| WO2017062270A1 (en) | Inhibition of autism spectrum disorder using decoy antigens to maternal brain-reactive antibodies | |
| JP2005528080A5 (https=) | ||
| Brendza et al. | Amyloid-β immunotherapies in mice and men | |
| Sauvé et al. | Tanycytic degeneration impairs tau clearance and contributes to Alzheimer’s disease pathology |